A Study to See How Well and How Safely Different Treatments Work in a Group of Participants With Non-Small Cell Lung Cancer (NSCLC)

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

November 18, 2024

Primary Completion Date

June 13, 2028

Study Completion Date

March 31, 2033

Conditions
Non-Small Cell Lung Cancer
Interventions
DRUG

Alectinib

"Cohort B1: participants will receive oral alectinib twice daily (BID) for up to 5 years.~Cohort B2: Participants will receive oral alectinib BID for 3 cycles (cycle length = 3 weeks) prior to surgery, and for up to 5 years after surgery."

DRUG

Cisplatin

"Cohort B1: Participants will receive intravenous (IV) cisplatin on Day 1 of each cycle for up to 4 cycles (cycle length = 3 weeks).~Cohort B2: Participants will receive IV cisplatin on Day 1 of each cycle for up to 3 cycles (cycles length = 3 weeks) prior to surgery."

DRUG

Carboplatin

"Cohort B1: Participants will receive IV carboplatin on Day 1 of each cycle for up to 4 cycles (cycle length = 3 weeks).~Cohort B2: Participants will receive IV carboplatin on Day 1 of each cycle for up to 3 cycles (cycle length = 3 weeks) prior to surgery."

DRUG

Pemetrexed

"Cohort B1: Participants will receive IV pemetrexed on Day 1 of each cycle for up to 4 cycles (cycle length = 3 weeks).~Cohort B2: Participants will receive IV pemetrexed on Day 1 of each cycle for up to 3 cycles (cycle length = 3 weeks) prior to surgery."

Trial Locations (37)

1023

Auckland City Hospital, Cancer and Blood Research, Auckland

2065

Royal North Shore Hospital, St Leonards

6009

Sir Charles Gairdner Hospital, Nedlands

10300

Oncology Unit, Faculty of Medicine, Vajira Hospital, Dusit

10700

Faculty of Med. Siriraj Hosp., Bangkok

11590

Clinical Research Alliance, Westbury

13005

CHU Timone, Marseille

16247

St. Vincent's Hospital, Gyeonggi-do

29010

Hospital Regional Universitario Carlos Haya, Málaga

33600

CHU de Bordeaux, Pessac

38120

Baptist Cancer Center, Memphis

40002

Srinagarind Hospital, Khon Kaen

50200

Maharaj Nakorn Chiang Mai Hosp, Chang Mai

67091

CHU Strasbourg - Nouvel Hopital Civil, Strasbourg

69008

Centre Leon Berard, Lyon

80045

University of Colorado Anschutz Medical Campus, Aurora

100142

Beijing Cancer Hospital, Beijing

410008

Xiangya Hospital of Centre-South University, Changsha

430030

Tongji Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan

510000

Guangdong General Hospital, Guangzhou

650118

Yunnan Cancer Hospital, Kunming

95070-560

Universidade de Caxias do Sul - Rio Grande do Sul, Caxias do Sul

90035-903

Hospital de Clínicas de Porto Alegre X, Porto Alegre

90610-000

Hospital Sao Lucas - PUCRS, Porto Alegre

14784-400

Hospital de Cancer de Barretos, Barretos

15090-000

Hospital de Base de Sao Jose do Rio Preto, São José do Rio Preto

01246-000

Instituto do Cancer do Estado de Sao Paulo - ICESP, São Paulo

Unknown

RedSalud Vitacura, Santiago

The third people's hospital of Chengdu, Chengdu

Jinhua municipal central hospital, Jinhua

06156

Azienda Ospedaliera Di Perugia Ospedale s. Maria Della Misericordia, Perugia

04700

Centro Oncologico Internacional, Mexico City

06700

ARKE Estudios Clínicos S.A. de C.V., Mexico City

03722

Severance Hospital, Yonsei University Health System, Seoul

05505

Asan Medical Center, Seoul

06351

Samsung Medical Center, Seoul

08035

Hospital Universitari Vall d'Hebron, Barcelona

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT06624059 - A Study to See How Well and How Safely Different Treatments Work in a Group of Participants With Non-Small Cell Lung Cancer (NSCLC) | Biotech Hunter | Biotech Hunter